Viking Therapeutics Inc VKTX

US Biotechnology
$31.74 β–Ό -4.14% ($-1.37)
🔥 High Short Interest
Open $33.40
Prev Close $33.11
Day Range $31.48 – $33.75
52W Range $22.96 – $43.15
Market Cap $3.70B
Beta 0.66
EPS (TTM) $-4.15

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2015-04-29
Shares Out.116,650,000
Websitevikingtherapeutics.com/ β†—
Phone18009279800
Employees59
Net Income-$128.0M
Total Assets$521.9M
Total Liabilities$113.6M
Equity$408.3M
About Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Inc is a publicly traded company under the ticker symbol VKTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

26 analysts (2026-07-01)

Strong Buy 9
Buy 14
Hold 3

πŸ“° Latest News for VKTX

πŸ‘₯ Related Stocks